| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/12/2002 | US6346098 Methods and kits for locally administering an active agent to an interstitial space of a host |
| 02/12/2002 | CA2259152C Adenovirus e4 proteins for inducing cell death |
| 02/12/2002 | CA2223776C Method of treatment for lung diseases using antisense oligonucleotides |
| 02/07/2002 | WO2002010428A2 Tissue-associated proteins and their uses |
| 02/07/2002 | WO2002010418A2 Targeting through integrins |
| 02/07/2002 | WO2002010410A1 Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses |
| 02/07/2002 | WO2002010408A1 Expression vector coding p972 gene for cancer therapy and adenovirus producing the same |
| 02/07/2002 | WO2002010403A2 Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme |
| 02/07/2002 | WO2002010402A2 Isolation of drosophila and human polynucleotides encoding par-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides |
| 02/07/2002 | WO2002010401A2 18431 and 32374, human protein kinase family members and uses therefor |
| 02/07/2002 | WO2002010392A2 Mammalian dna binding membrane-associated protein-encoding gene and uses |
| 02/07/2002 | WO2002010389A2 Human ion channel proteins and polynucleotides encoding the same |
| 02/07/2002 | WO2002010388A2 C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF |
| 02/07/2002 | WO2002010387A2 G-protein coupled receptors |
| 02/07/2002 | WO2002010379A2 Modified cea and uses thereof |
| 02/07/2002 | WO2002010378A2 Antisense modulation of ptp1b expression |
| 02/07/2002 | WO2002010375A1 Human source gene leading sequence, gene vector and gene expression strategy |
| 02/07/2002 | WO2002010371A1 Novel physiologically active peptide and use thereof |
| 02/07/2002 | WO2002010368A1 Tumor-specific promoters |
| 02/07/2002 | WO2002010364A2 Methods for enhancing targeted gene alteration using oligonucleotides |
| 02/07/2002 | WO2002010357A2 Gsk3 polypeptides |
| 02/07/2002 | WO2002010346A2 Insulin producing cell-line obtained by electrofusion |
| 02/07/2002 | WO2002010217A2 Endothelial cell expression patterns |
| 02/07/2002 | WO2002010216A2 Proteins and nucleic acids encoding same |
| 02/07/2002 | WO2002010214A2 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| 02/07/2002 | WO2002010198A2 Polynucleotides and polypeptides |
| 02/07/2002 | WO2002010197A1 Cationic amphipathic peptides and the application thereof in gene transfer vectors |
| 02/07/2002 | WO2002010185A1 Antisense modulation of lysophospholipase i expression |
| 02/07/2002 | WO2002009770A1 Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
| 02/07/2002 | WO2002009696A1 Methods for treating cell proliferative disorders and viral infections |
| 02/07/2002 | WO2002009644A2 Angiogenic and osteogenic proteins for use in enhancing bone density and formation |
| 02/07/2002 | WO2002009639A2 Methods and pharmaceutical compositions for healing wounds |
| 02/07/2002 | WO2002009507A1 Somatic cloning gene transfer for the production of recombinant proteins, cells and organs |
| 02/07/2002 | WO2001075066A3 Dna molecules and polypeptides of pseudomonas syringae hrp pathogenicity island and their uses |
| 02/07/2002 | WO2001072339A3 Method of treatment of conditions involving obstruction of blood flow |
| 02/07/2002 | WO2001072119A3 Non-human animal model for growth deficiency and information processing or cognitive function defects and use thereof |
| 02/07/2002 | WO2001064238A3 Methods and compositions for regulating adipocytes |
| 02/07/2002 | WO2001062790A3 Nuclear factor polypeptides and nucleic acids encoding same |
| 02/07/2002 | WO2001057193A3 Protein c derivatives |
| 02/07/2002 | WO2001055315A3 Nucleic acids, proteins, and antibodies |
| 02/07/2002 | WO2001055211A3 Fil-1 theta dnas and polypeptides |
| 02/07/2002 | WO2001053347A3 Nphs2 gene involved in the cortico-resistant neprhotic syndrome, protein encoded by said gene and diagnostic and therapeutic uses |
| 02/07/2002 | WO2001042487B1 Device for extraction of nucleic acids |
| 02/07/2002 | WO2001042449A3 Methods for introducing genes into mammalian subjects |
| 02/07/2002 | WO2001035935B1 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer |
| 02/07/2002 | WO2001034206A3 Nucleic acid-containing complex |
| 02/07/2002 | WO2001029233A3 Chimeric immunogenic compositions and nucleic acids encoding them |
| 02/07/2002 | WO2001029226A3 Apoptosis inducing proteinaceous substance |
| 02/07/2002 | WO2001025415A3 Gene transfer in human lymphocytes using retroviral scfv cell targeting |
| 02/07/2002 | WO2001002587A3 Novel antifungal agents and fungicides, method for the production thereof and their use |
| 02/07/2002 | WO2000068376A8 Novel chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same |
| 02/07/2002 | WO2000060117A3 Prediction of risk of interstitial lung disease |
| 02/07/2002 | US20020016976 Mutant multi-substrate enzyme which accepts at least one orthogonal substrate analog, whereby catalytic activity results in combination of all or part of orthogonal substrate with other substrate of enzyme; drug screening |
| 02/07/2002 | US20020016625 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 02/07/2002 | US20020016305 Yeast genes that affect viral replication |
| 02/07/2002 | US20020016304 Carrier for stabilizing nucleic acid |
| 02/07/2002 | US20020016303 Genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. |
| 02/07/2002 | US20020015981 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 02/07/2002 | US20020015980 Neurotransmitter transporter |
| 02/07/2002 | US20020015945 Method for the purification of alphavirus replicon particles |
| 02/07/2002 | US20020015695 Herpesviral vectors for gene delivery |
| 02/07/2002 | US20020014242 Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products |
| 02/07/2002 | DE10053879A1 Genexpression, Genomalteration und Reporterexpression in Myofibroblasten und myofibroblast-ähnlichen Zellen Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells |
| 02/07/2002 | DE10035433A1 Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben Gentle high enrichment of fetal cells from blood pripherem and using the same |
| 02/07/2002 | CA2418072A1 Insulin producing cell-line obtained by electrofusion |
| 02/07/2002 | CA2417900A1 C3b/c4b complement receptor-like molecules and uses thereof |
| 02/07/2002 | CA2417642A1 Novel human ion channel proteins and polynucleotides encoding the same |
| 02/07/2002 | CA2417568A1 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| 02/07/2002 | CA2417495A1 Methods for treating cell proliferative disorders and viral infections |
| 02/07/2002 | CA2417364A1 Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses |
| 02/07/2002 | CA2417349A1 Novel proteins and nucleic acids encoding same |
| 02/07/2002 | CA2417344A1 Methods for enhancing targeted gene alteration using oligonucleotides |
| 02/07/2002 | CA2417195A1 G-protein coupled receptors |
| 02/07/2002 | CA2417087A1 Mammalian dna binding membrane-associated protein-encoding gene and uses |
| 02/07/2002 | CA2416893A1 Modified cea and uses thereof |
| 02/07/2002 | CA2416877A1 Somatic cloning gene transfer for producing recombinant proteins, cells and organs |
| 02/07/2002 | CA2416800A1 Isolation of drosophila and human polynucleotides encoding par-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides |
| 02/07/2002 | CA2416788A1 Methods and pharmaceutical compositions comprising protein kinase c isoforms for healing wounds |
| 02/07/2002 | CA2416732A1 Endothelial cell expression patterns |
| 02/06/2002 | EP1178117A1 Targeting through integrins |
| 02/06/2002 | EP1178116A1 Sid nucleic acids and polypeptides selected from a pathogenic strain of hepatitis C virus and applications thereof |
| 02/06/2002 | EP1178115A2 Phosphodiesterase |
| 02/06/2002 | EP1178053A2 Polypeptides and polynucleotides coding therefor from a family of G-protein coupled receptors and their use for the diagnosis and treatment of skin diseases |
| 02/06/2002 | EP1178052A2 Genes identified as required for proliferation in Escherichia coli |
| 02/06/2002 | EP1177301A2 $i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF |
| 02/06/2002 | EP1177298A1 Autotaxin variants and uses to treat diseases of metabolism |
| 02/06/2002 | EP1177296A2 Extracellular matrix and adhesion-associated proteins |
| 02/06/2002 | EP1177295A1 Ox2 receptor homologs |
| 02/06/2002 | EP1177288A1 Tumour-associated antigen |
| 02/06/2002 | EP1177286A1 Mdm interacting protein and methods of use thereof |
| 02/06/2002 | EP1177285A1 Chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same |
| 02/06/2002 | EP1177215A1 Constitutive chimeric receptors, and methods of use thereof |
| 02/06/2002 | EP1176968A2 Selenium-containing pro-drugs for cancer therapy |
| 02/06/2002 | EP1176965A1 Antisense modulation of fas mediated signaling |
| 02/06/2002 | EP1176870A2 Tgf-alpha polypeptides, functional fragments and methods of use therefor |
| 02/06/2002 | EP0866865B1 Chimeric oligomers having an rna-cleavage activity |
| 02/06/2002 | EP0832267B1 Adenovirus vectors for gene therapy |
| 02/06/2002 | CN1334878A Polynucleotide comprising ubiquitous chromatin opening element (UCDE) |
| 02/06/2002 | CN1334875A Cell signalling polypeptides and nucleic acids |
| 02/06/2002 | CN1334820A Connective tissue growth factor fragments and methods and uses thereof |